Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study

Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study

Abstract Background In patients with idiopathic pulmonary fibrosis (IPF) treated with pirfenidone (Esbriet®, Genentech USA, Inc. South San Francisco, CA.), effectively managing treatment-related adverse events (AEs) may improve adherence. Due to a lack of clinical evidence and expertise, managing th...

Full description

Bibliographic Details
Main Authors: Franck F. Rahaghi, Zeenat Safdar, Anne Whitney Brown, Joao A. de Andrade, Kevin R. Flaherty, Robert J. Kaner, Christopher S. King, Maria L. Padilla, Imre Noth, Mary Beth Scholand, Adrian Shifren, Steven D. Nathan
Format: Article
Language:English
Published: BMC 2020-07-01
Series:BMC Pulmonary Medicine
Subjects:
Adverse events
Idiopathic pulmonary fibrosis
Management
Pirfenidone
Expert consensus
Online Access:http://link.springer.com/article/10.1186/s12890-020-01209-4

Internet

http://link.springer.com/article/10.1186/s12890-020-01209-4

Similar Items